

**Amryt EASE study opens for recruitment at Children's Hospital of Philadelphia (CHOP), Philadelphia, PA and Stony Brook Dermatology, Stony Brook, New York**

Amryt, a company focused on developing products that help to improve the lives of patients where there is a high unmet medical need, announce that **Leslie Castelo-Soccio, MD, Ph.D., Children's Hospital of Philadelphia, and Jordan Slutsky, MD, Stony Brook Dermatology, Stony Brook, NY**, join **Anna Bruckner, MD, Children's Hospital of Colorado in Denver, CO, and John Browning, MD, Texas Dermatology and Laser Specialist, San Antonio, TX**. As study sites for Amryt's phase III trial in EB, EASE. All of these sites are open to recruit eligible patients with Epidermolysis Bullosa (EB) into the Global EASE study. The EASE study is evaluating Oleogel-S10, an investigational topical treatment for the wounds associated with inherited EB.

Up to 10 trial sites are planned in the US and initiation of **Children's Hospital of Philadelphia (PA) and Stony Brook Dermatology (Stony Brook Medicine), Stony Brook, NY** is a significant milestone in accelerating patient recruitment into the EASE study. The EASE study has existing trial sites in Europe, Australasia, Latin America and the Middle East. The US Food and Drug Administration ("FDA") granted Investigational New Drug ("IND") clearance for the EASE study in September 2018.

Up to date information about the EASE study, including study design, study site information, and how to contact a site directly is available on [clinicaltrials.gov](https://clinicaltrials.gov)

Amryt is encouraged by this news. The opening of additional new study sites, along with the recent outcome of the pre-specified interim efficacy analysis resulting in the modest increase in patient enrollment to 230 subjects required for adequate statistical power. In addition, the pre-specified safety analysis results extending the age eligibility criteria to patients aged 21 days and older, is positive news and a significant step forward in addressing the unmet need in this devastating condition. The EASE trial is the largest ever global Phase III study conducted in patients with EB. Amryt would like to thank sincerely the patients, families and clinical investigators involved in the EASE trial.